Comparator Types and Sourcing Models

Comparator type is the first specification decision in any clinical trial comparator procurement, since it determines which of the four sourcing models in the comparator sourcing market are actually viable for a given trial, rather than sourcing model being an independent choice a sponsor can make freely.

A branded drug still under patent protection with a single manufacturer and limited distribution partners narrows sourcing options considerably compared with a widely available generic with multiple qualified suppliers, and sponsors that treat sourcing model selection as a downstream consequence of comparator type, rather than a parallel decision, typically shorten their overall procurement timeline.

This distinction matters most at the point a trial protocol is amended to add or swap a comparator arm, since a sourcing team that has already mapped which sourcing models each comparator type supports can requalify a new comparator against an existing procurement pathway far faster than starting the sourcing model evaluation from scratch.

In practice, a sourcing team typically starts by confirming which countries in a trial's footprint have the comparator approved and commercially available at all, since that single check determines whether open-market procurement is even on the table before any sourcing model comparison begins.

Sponsors that treat this evaluation as a standing checklist, applied consistently at the start of every new trial regardless of therapeutic area, tend to identify a sourcing constraint earlier than those relying on ad hoc judgement calls made independently by each individual trial team.

Branded Drugs and Generics

Branded drug comparators, particularly those still under patent exclusivity or with a single approved manufacturer, generally require either a direct manufacturer relationship or an authorized distributor agreement, since open-market procurement channels for a still-patented branded product are frequently unavailable or carry higher diversion and counterfeiting risk.

Generic comparators, by contrast, typically have multiple approved manufacturers and established distribution channels, making open-market procurement a viable and often preferred sourcing model given its shorter lead time and lower per-unit cost relative to a negotiated direct manufacturer agreement.

Pricing and lead time for generic comparator sourcing also vary meaningfully by manufacturing region, with sponsors increasingly qualifying more than one generic supplier per comparator to reduce single-source dependency risk across a multi-year trial.

Manufacturers of branded comparators increasingly maintain a dedicated clinical trial supply function separate from their commercial distribution arm, reflecting the distinct compliance, volume and lead-time requirements of a trial supply relationship relative to standard commercial pharmacy distribution.

Contract structures also differ meaningfully between the two comparator types: a branded drug sourcing agreement often includes minimum order commitments and multi-year pricing terms reflecting the manufacturer's own limited production allocation for third-party clinical use, while a generic sourcing agreement more closely resembles a standard commercial procurement contract with shorter commitment periods.

Sourcing teams evaluating a branded comparator also increasingly assess the manufacturer's own clinical trial supply policy early in trial design, since some manufacturers maintain a formal third-party clinical supply programme with published terms, while others require case-by-case negotiation that can add weeks to the initial sourcing timeline.

Branded comparator sourcing typically involves a longer lead time than the equivalent generic, since a manufacturer supplying a branded product for trial use often requires a separate clinical supply agreement distinct from its commercial distribution channel, while a generic manufacturer's more standardised commercial supply chain can frequently accommodate a trial order through existing distribution relationships with a shorter negotiation cycle.

Biosimilars and Investigator-Initiated Medicines

Biosimilar comparators introduce sourcing complexity beyond a standard generic, since regulatory interchangeability rules and manufacturer-specific approval pathways differ by jurisdiction, meaning a biosimilar comparator qualified for use in one trial country may not carry equivalent regulatory standing in another.

Investigator-initiated medicines, sourced for trials led by an individual investigator or academic institution rather than a commercial sponsor, frequently rely on donated product, reduced-cost manufacturer agreements, or smaller-volume open-market purchases, reflecting the typically constrained procurement budget of an investigator-led trial relative to a commercially sponsored study.

Cold chain handling requirements are also more common among biosimilar comparators than among small-molecule generics, adding a further sourcing model consideration that interacts with the delivery format decisions covered elsewhere in this report.

A sponsor evaluating a biosimilar comparator for a multi-country trial typically confirms interchangeability status country by country before finalising trial design, since discovering a regulatory gap after site activation has begun is materially more disruptive than identifying it during protocol planning.

Investigator-initiated trials sourcing an investigational combination partner alongside a comparator sometimes face a compounded sourcing challenge, since two separate supply relationships must be coordinated on the same trial timeline, each potentially subject to a different sourcing model and lead time.

Biosimilar manufacturers have also begun publishing clearer clinical trial supply policies in recent years, following the pattern established by branded originator manufacturers, gradually reducing the historical sourcing-timeline gap between biosimilar and branded comparator procurement even as jurisdiction-specific interchangeability rules remain a persistent complication.

Direct Manufacturer Sourcing and Authorized Distributors

Direct manufacturer sourcing offers the highest supply chain traceability and typically the strongest documentation support for regulatory filing purposes, but requires establishing a bespoke commercial agreement per comparator per trial, a process that can extend procurement lead time by several months for a first-time relationship.

Authorized distributor relationships trade some of that direct traceability for materially faster fulfilment on an already-established supply chain, since a distributor with an existing manufacturer relationship can typically fulfil a comparator order without negotiating a new bespoke agreement for each trial.

Sponsors running trials that span multiple trial phases and therapeutic areas within a single comparator programme often use a hybrid approach, establishing a direct manufacturer relationship for the highest-volume Phase III need while relying on an authorized distributor for smaller Phase I and Phase II quantities.

The choice between these two sourcing models also affects contract renewal cycles: a direct manufacturer agreement negotiated for one trial can sometimes be extended to cover a related follow-on study, while an authorized distributor relationship is typically re-quoted per order, giving direct sourcing a potential long-term cost advantage for a sponsor running a multi-study comparator programme.

A sponsor's internal legal and procurement review process also tends to move faster for an authorized distributor relationship than for a bespoke direct manufacturer agreement, since a distributor relationship typically follows a more standardised contract template that a sponsor's legal team has already reviewed for a prior trial.

Quality agreements accompanying either sourcing model also warrant early legal review, since the specific quality and pharmacovigilance obligations a sponsor accepts can differ meaningfully between a direct manufacturer relationship and a distributor arrangement, even when the underlying comparator product itself is identical.

A growing number of manufacturers now offer a hybrid arrangement combining elements of both models, granting a sponsor direct-sourcing pricing terms while routing physical fulfilment through an authorized distributor's existing logistics network, capturing much of the cost benefit of direct sourcing without the fulfilment delay of building a bespoke distribution pathway from scratch.

Open-Market Procurement and Named Patient Programs

Open-market procurement, purchasing an already-commercially-available comparator through standard pharmaceutical distribution channels, is the fastest and generally lowest-cost sourcing model, but is only viable when the comparator is approved and commercially available in every country where the trial is running.

Named Patient Programs provide a regulated pathway to source a comparator that is not yet approved, or not yet commercially available, in a specific trial country, typically requiring country-specific regulatory authorization for each patient enrolled and carrying materially longer lead times than open-market procurement.

Named Patient Program usage has grown alongside the increase in multi-country trials that include at least one country where a given comparator lacks local approval, a dynamic that leading comparator sourcing providers increasingly build dedicated regulatory-affairs teams to manage.

Sponsors increasingly track open-market comparator availability on an ongoing basis rather than only at trial initiation, since a comparator that is openly available today can lose that status if a manufacturer discontinues a product line or shifts distribution strategy mid-trial.

Some sourcing providers now offer a hybrid monitoring service that tracks a comparator's open-market status on an ongoing basis and automatically flags a sponsor when a shift toward restricted availability is detected, letting a sourcing team pre-emptively transition to a Named Patient Program or distributor relationship before a supply gap actually occurs.

Documentation requirements for a Named Patient Program application also tend to be more sponsor-specific than standardised across providers, meaning a sourcing team's familiarity with a particular country's application format can materially shorten the actual authorization timeline relative to a provider navigating that country's process for the first time.

Named patient programs, used when a trial requires access to a product not yet commercially available in a given country, add a regulatory approval step on top of the sourcing transaction itself, since the importing country's own named-patient or compassionate-use framework must authorise each individual shipment before it can proceed, a process that runs on a materially longer and less predictable timeline than routine open-market procurement of an already-approved product.